Current Perspectives in the Treatment of Locally Advanced Basal Cell Carcinoma [PDF]
Drug Design, Development and Therapy, 2022 Neha Gupta, Emily S Ruiz Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Jamaica Plain, MA, USACorrespondence: Emily S RuizDepartment of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, 1153 Centre ...
Gupta N, Ruiz ES
doaj +6 more sources
Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study [PDF]
Acta Dermato-Venereologica, 2022 Sonidegib, a hedgehog pathway inhibitor, is indicated for treatment of locally advanced basal cell carcinoma, based on the results of the BOLT study. However, to date, no real-world study of sonidegib has been reported.
Florian Herms +6 more
doaj +4 more sources
Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study) [PDF]
EClinicalMedicine, 2021 Background: Surgery is the primary treatment for basal cell carcinoma (BCC). In locally advanced basal cell carcinoma (laBCC), surgery may cause functional or aesthetic damage.
Nicolas Bertrand, MD +9 more
doaj +4 more sources
Vismodegib and orbital excision for treating locally advanced basal cell carcinoma [PDF]
International Medical Case Reports Journal, 2018 Daniel T Hogarty,1 Nicholas G Dewhurst,1 Benjamin Burt1–4 1Bendigo Eye Clinic, Bendigo, VIC, Australia; 2Royal Victorian Eye and Ear Hospital, Melbourne, VIC, Australia; 3Cosmetic Surgery for Women, Melbourne, VIC, Australia; 4Canberra ...
Hogarty DT, Dewhurst NG, Burt B
doaj +5 more sources
Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry [PDF]
PLoS ONE, 2022 Background Limited information is available regarding real-world treatment patterns and their effectiveness and safety in patients with locally advanced basal cell carcinoma, including patients not typically represented in clinical trials. The purpose of
Aleksandar Sekulic +12 more
doaj +3 more sources
Benefit–risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma [PDF]
Drugs in Context, 2022 Background: Sonidegib and vismodegib are Hedgehog pathway inhibitors (HhIs) that play a relevant role in the management of locally advanced basal cell carcinoma (laBCC).
Antonio J García Ruiz +4 more
doaj +2 more sources
Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.
Dermatology, 2023 Background: Vismodegib is a first-in-class inhibitor of the hedgehog pathway for treatment of locally advanced basal cell carcinoma (laBCC) and metastatic BCC. Objectives: The purpose of this study is to report outcomes of patients with laBCC, with basal cell carcinoma nevus syndrome (Gorlin Goltz syndrome [G-G Syn]) treated with vismodegib in routine ...
Mesti T, Sever M, Ocvirk J.
europepmc +5 more sources
Sonidegib Therapy for Locally Advanced Basal Cell Carcinoma in an Elderly Patient: A Case Report [PDF]
Clinical, Cosmetic and Investigational DermatologyYuyu Deng,1– 5 Pingxiu He,1– 5 Changxia Li,1– 5 Guolan Li,1– 5 Xiaohua Tao1– 5 1Dermatology Department, Dermatology Hospital of Jiangxi Province, Nanchang, Jiangxi, People’s Republic of China; 2Dermatology Department, Jiangxi Provincial Clinical Research
Deng Y, He P, Li C, Li G, Tao X
doaj +2 more sources
The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular Area [PDF]
Dermatology and Therapy, 2023 Introduction Basal cell carcinoma (BCC) is the most common skin malignancy in Caucasians. Globally, about 20% of BCCs involve the periocular region. The treatment of periocular BCC may be very challenging because of its proximity to the intracranial ...
Alessia Villani +5 more
doaj +2 more sources
Survey of the impact of BOLT-trial data on oncologists’ and dermatologists’ decision-making in treating patients with locally advanced basal cell carcinoma [PDF]
Dermatology ReportsBasal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multiple studies demonstrated that the aberrant activation of Hedgehog signaling is a driver of BCC development, and its blockade represents a potential therapeutic ...
Luigi Scarpato +9 more
doaj +2 more sources